The Department of Neurology is pleased to announce 57 of our faculty members have been selected for the 2023 Castle Connolly Top Doctors® and Rising Stars lists. We are proud of our physicians for their hard work and dedication to their patients each and every day. Each year, Castle Connolly uses a merit-based system to […]
Under normal circumstances, tau protein is part of the brain’s infrastructure, important for stabilizing neurons into their proper shapes. But sometimes tau gets knotted up into tangles and turns toxic, injuring brain tissue and causing tauopathies, a group of brain diseases characterized by problems with learning, memory and movement. Alzheimer’s disease is the most common […]
Ischemic stroke in the pediatric population is rare; however, stroke in children in the acute setting can be missed because of its low prevalence. Care for acute pediatric strokes involves determining the most likely etiology in a timely manner, understanding available resources, and making the best choice based on the information at hand, according to […]
Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, discusses the promise of blood-based biomarkers for treatment monitoring. Data has been presented on plasma phosphorylated-tau 217 (p-tau217) as a method to monitor the effects of lecanemab and donanemab. This research is investigating if medication discontinuation is feasible if p-tau217 […]
The Food and Drug Administration (FDA) recently gave full approval to Leqembi (lecanemab) for patients in the early stages of Alzheimer’s disease. Physicians and researchers at Washington University School of Medicine’s Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) in St. Louis were involved in the clinical trials evaluating Leqembi, in which they enrolled […]
The city of St. Louis has the highest rate of Alzheimer’s dementia cases in Missouri, and new evidence from Washington University’s School of Medicine shows that social factors like income, race and education play a role in access to treatment and diagnosis. The new observational study, focused on the Washington University Memory Diagnostic Center, showed […]
Nearly every person with Down syndrome eventually develops Alzheimer’s disease, yet people with the syndrome routinely are excluded from Alzheimer’s clinical trials, as the cognitive assessment tools designed for the general population often are inappropriate for people with developmental disabilities. Consequently, nobody knows whether the new Alzheimer’s therapeutics hitting the market will work for people […]
Patients who live in less affluent neighborhoods and those from underrepresented racial or ethnic groups are less likely than others to receive specialized care for dementia, including Alzheimer’s disease, a new study from Washington University School of Medicine in St. Louis indicates. Further, the research shows that Black people are more likely than white people […]
The Department of Neurology congratulates former Neurology Research Lab Manager Cynthia Hodge for being awarded the Neurology Staff Employee of the Quarter for Q4 FY23. Hodge was nominated by faculty and staff because of her hard work and dedication to her role and the people she manages. Those who nominated her, in particular, highlighted how […]
Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, gives insight into the need for more diverse cohorts to improve our understanding of the impact of sex, age, and race on biomarker levels and trajectories in Alzheimer’s disease. While efforts to study racial and ethnic minority populations have improved, […]